Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances. For more information, visit ocuphire.com #ophthalmology #optometry

Ocuphire to Present at Five Upcoming Investor/Industry Conferences bit.ly/3tPDXAC

Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis bit.ly/3F4JHeL

.Ocuphire Pharma announces the submission of a NDA to the FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the reversal of pharmacologically-induced #mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents, or a combination thereof. bit.ly/3HcMh5h

ICYMI: Ocuphire Pharma submits new drug application for eye drops for reversal of mydriasis More: ow.ly/O2oO50LXrcb #Optometry #Pipeline #Pediatrics

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia bit.ly/3ZnV7DW

First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia More: ow.ly/LsOU50Mlrzy #Optometry #Presbyopia #ClinicalTrial #Clinical Ocuphire Pharma

Join Mina Sooch, CEO, Charlie Hoffmann, VP, Corporate Development and Operations, and the management team at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. #jpm2023 $OCUP #jpm23 Reach out to Investor Relations at [email protected] to connect.

Thank you, Optometry Times, for the opportunity to share our corporate highlights at the American Academy of Optometry meeting in Sunny San Diego! #Presbyopia #reversalofMydriasis #NightVisionDisturbances #diabeticnephropathy Bindu Manne

First patient enrolled in Ocuphire Phase 3 pivotal trial of Nyxol for presbyopia More: ow.ly/JPJG50MqpGw #Optometry #Presbyopia Ocuphire Pharma

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for... bit.ly/3DbbFoX

After phase II miss, Ocuphire Pharma to seek a visual from U.S. FDA on next steps in DR bioworld.com/articles/69367… #biotech #pharma

.Ocuphire Pharma announced topline efficacy and safety results from its ZETA-1 phase 2 trial evaluating oral APX3330 for the treatment of #diabeticretinopathy (DR). bit.ly/3DnvlGj

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye... bit.ly/3YImMya

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings bit.ly/3xsskBl

🙏Fortunate to present the results from the ZETA-1 study by Ocuphire on reducing the progression of diabetic retinopathy👁️with a first in class oral 💊agent. Promising results to help our patients see better.

Thank you Dr. Rishi P. Singh MD for presenting at #MaculaSociety2023 #diabeticretinopathy

linkedin.com/posts/ocuphire…

It’s #InternationalWomensDay everyday at Ocuphire. Cheers to a female led company! linkedin.com/posts/ocuphire…

Oral APX3330 outperformed placebo in slowing progression of #diabeticretinopathy in the phase 2 ZETA-1 trial, according to results presented by Ocuphire Pharma at the virtual Angiogenesis, Exudation and Degeneration 2024 conference. Ocular Surgery News Read more! 👇 bit.ly/4bv6D6u